This content is from: Patents

Obviousness-type double patenting spurs need for careful counsel

Pharmaceutical companies in the US tell Managing IP that it’s important to have considered and knowledgeable law firm partners when tackling this increasingly challenging legal doctrine

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial